Loading...

Alexa Fluor® 700 anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_Alx700_020608
C57BL/6 mouse splenocytes stained with 30-F11 Alexa Fluor® 700
  • 30-F11_Alx700_020608
    C57BL/6 mouse splenocytes stained with 30-F11 Alexa Fluor® 700
  • 54_Mouse_Liver_Ecadherin_CD45
    Confocal image of C57BL/6 mouse liver sample acquired using the IBEX method of highly multiplexed antibody-based imaging: E-Cadherin (red) in Cycle 1 and CD45 (cyan) in Cycle 3. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See Alexa Fluor® 700 spectral data
Cat # Size Price Quantity Check Availability Save
103127 25 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103128 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Stoupa A, et al. 2018. EMBO Mol Med. 10:. PubMed
  2. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  3. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  4. Tomida S, et al. 2019. Sci Rep. 9:10751. PubMed
  5. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  6. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  7. Daskou M, et al. 2022. PLoS Pathog. 18:e1010160. PubMed
  8. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  9. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  10. Trittel S, et al. 2019. Sci Rep. 9:16362. PubMed
  11. Fu R, et al. 2020. Sci Rep. 10:1455. PubMed
  12. Guzzi N et al. 2018. Cell. 173(5):1204-1216 . PubMed
  13. Wong Fok Lung T, et al. 2020. Nat Microbiol. 141:5. PubMed
  14. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  15. Ren Z, et al. 2021. EMBO Molecular Medicine. :e14059. PubMed
  16. Chen J, et al. 2021. Sci Adv. 7:. PubMed
  17. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  18. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  19. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  20. Gimblet C et al. 2017. Cell host & microbe. 22(1):13-24 . PubMed
  21. Putnam NE, et al. 2019. PLoS Pathog. 15:e1007744. PubMed
  22. Xi H, et al. 2016. J Exp Med. 213: 189 - 207. PubMed
  23. Hu X, et al. 2016. Nat Commun. 7:13095. PubMed
  24. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
  25. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  26. Fujii Y, et al. 2022. JBMR Plus. 6:e10562. PubMed
  27. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  28. Katsura A, et al. 2017. Mol Oncol. 11:1241. PubMed
  29. Amir M, et al. 2018. Cell Rep. 25:3733. PubMed
  30. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  31. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  32. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  33. McDowell SAC, et al. 2021. Nat Cancer. 2:545. PubMed
  34. Reyes RM, et al. 2021. Oncoimmunology. 10:2006529. PubMed
  35. Wang X, et al. 2020. Signal Transduct Target Ther. 5:35. PubMed
  36. Egusquiza RJ, et al. 2020. Environ Health Perspect. 128:47011. PubMed
  37. Evren E, et al. 2020. Immunity. 54(2):259-275.e7. PubMed
  38. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  39. van Elsas MJ, et al. 2022. Int J Mol Sci. 23:. PubMed
  40. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  41. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  42. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  43. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  44. Yang R, et al. 2012. J Immunol. 189:2656. PubMed
  45. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  46. Fantauzzi MF, et al. 2021. ERJ Open Res. 7: . PubMed
  47. Daubeuf F, et al. 2021. Cells. 10:. PubMed
  48. An J, et al. 2022. iScience. 25:103570. PubMed
  49. Chen ELY, et al. 2021. Cell Rep. 35:109227. PubMed
  50. Menzel L, et al. 2022. STAR Protoc. 3:101267. PubMed
  51. Abu El Maaty MA, et al. 2022. Sci Adv. 8:eabo2295. PubMed
  52. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  53. Daubeuf F, et al. 2017. Curr Protoc Mouse Biol. 10.1002/cpmo.26. PubMed
  54. Emgård J, et al. 2018. Immunity. 143:419. PubMed
  55. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  56. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  57. Sophie Thiemann et al. 2017. Cell host & microbe. 21(6):682-694 . PubMed
  58. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  59. Tanaka S, et al. 2012. J Immunol. 188:6145. PubMed
  60. Stutchfield B, et al. 2015. Gastroenterology. 149: 1896-1909.e14. PubMed
  61. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  62. Sun L, et al. 2020. J Immunol. 2177:204. PubMed
  63. Magupalli VG, et al. 2020. Science. :369. PubMed
  64. Li J, et al. 2020. Cancer Discov. . PubMed
  65. Duque-Correa MA, et al. 2022. Nat Commun. 13:1725. PubMed
  66. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  67. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  68. Tomlinson KL, et al. 2021. Nat Commun. 12:1399. PubMed
  69. Benne N, et al. 2020. Adv Healthc Mater. 9:e2000043. PubMed
  70. Prados A, et al. 2021. Nat Immunol. 22:510. PubMed
  71. Carozza JA, et al. 2020. Nat Cancer. 184:1. PubMed
  72. Levi J, et al. 2020. J Nucl Med. . PubMed
  73. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  74. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  75. Garcia LR, et al. 2021. Nat Commun. 12:3364. PubMed
  76. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  77. Zhao F, et al. 2022. Nat Commun. 13:6117. PubMed
  78. Hossain DMS, et al. 2018. J Clin Invest. 128:644. PubMed
  79. Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed
  80. Guérin MV, et al. 2019. Nat Commun. 10:4131. PubMed
  81. Li J, et al. 2018. Immunity. 49:178. PubMed
  82. Coursey T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.83. PubMed
  83. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  84. Riquelme SA, et al. 2020. Cell Metabolism. 31(6):1091-1106.e6. PubMed
  85. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  86. Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed
  87. Schmid MC, et al. 2022. Nat Commun. 13:1768. PubMed
  88. Chen X, et al. 2022. Front Immunol. 13:828319. PubMed
  89. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  90. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  91. O'Connor T, et al. 2020. Cancer Cell. 36(3):250-267. PubMed
  92. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
  93. Acker KP, et al. 2019. iScience. 19:281. PubMed
  94. McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed
  95. Abboud D, et al. 2015. Sci Rep. 5: 14746. PubMed
  96. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  97. Hiebert P et al. 2018. Developmental cell. 46(2):145-161 . PubMed
  98. Sitaraman S, et al. 2019. Sci Rep. 9:12509. PubMed
  99. Frank E, et al. 2016. Toxicol Pathol. 10.1177/0192623315620587. PubMed
  100. Zhang HG, et al. 2022. Cell Res. :. PubMed
  101. Zhai K, et al. 2021. Nat Cancer. 2:1136. PubMed
  102. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  103. Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed
  104. Leyva‐Castillo JM et al. 2019. Immunity. 50(5):1262-1275 . PubMed
  105. Avraham S, et al. 2019. Oncogene. 38:3812. PubMed
  106. Uderhardt S, et al. 2019. Cell. 177:541. PubMed
  107. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  108. Park HB, et al. 2020. Nat Microbiol. 1319:5. PubMed
  109. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  110. Kostadinova E, et al. 2016. Sci Rep. 6:30943. PubMed
  111. Nair S, et al. 2021. JCI Insight. 6:. PubMed
  112. Ma J, et al. 2021. J Transl Med. 19:477. PubMed
  113. Philip E Boulais et al. 2018. Immunity. 49(4):627-639 . PubMed
  114. Crauste F, et al. 2017. Cell Syst. 0.379166667. PubMed
  115. Clark JT, et al. 2021. eLife. 10:00. PubMed
  116. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  117. Ahn D, et al. 2021. Cell Reports. 35(9):109196. PubMed
  118. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  119. Stevenson ER, et al. 2022. J Pharmacol Exp Ther. 382:356. PubMed
  120. Murray MP, et al. 2022. Cell Rep. 38:110209. PubMed
  121. Dustin CM, et al. 2021. J Immunol. 206:2989. PubMed
  122. Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed
  123. Bollenbach M, et al. 2021. Molecules. 26:. PubMed
  124. Vacca F, et al. 2020. eLife. 9:e54017.. PubMed
  125. Ji G, et al. 2019. Bone Joint J. 101-B:108. PubMed
  126. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  127. Artham S, et al. 2020. Am J Physiol Lung Cell Mol Physiol. L750:318. PubMed
  128. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  129. Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed
  130. Zhang MS, et al. 2022. Nat Commun. 13:954. PubMed
  131. Liu W, et al. 2022. J Clin Invest. 132: . PubMed
  132. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  133. Ayturk UM, et al. 2020. J Bone Miner Res. 35:1981. PubMed
  134. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  135. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  136. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  137. Natale CA, et al. 2018. Elife. 7. PubMed
  138. Gicheva N, et al. 2016. Biochem Biophys Res Commun. 479:1-4. PubMed
  139. Zhang Z, et al. 2020. Front Immunol. 11:583276. PubMed
  140. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  141. Melhem NJ, et al. 2021. Circulation. 143:566. PubMed
  142. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  143. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  144. Aguilar-Pimentel A, et al. 2017. PLoS One. 12(6):e0178563. PubMed
  145. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  146. Hayashida E, et al. 2019. J Neuroinflammation. 0.789583333. PubMed
  147. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  148. Cambridge E, et al. 2017. Exp Hematol. 45:64-68.e5. PubMed
  149. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  150. Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed
  151. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  152. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  153. Korin B, et al. 2020. Sleep. :43. PubMed
  154. Van der Meer JM, et al. 2020. Cancer Immunol Immunother. . PubMed
  155. Molgora M, et al. 2020. Cell. 182:886. PubMed
  156. Dye BR, et al. 2020. Biomaterials. 234:119757. PubMed
  157. Lee GR, et al. 2021. JCI Insight. 6:. PubMed
  158. Chetty A, et al. 2021. Cell Host Microbe. 29:579. PubMed
  159. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  160. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  161. Hartwig T et al. 2017. Molecular cell. 65(4):730-742 . PubMed
  162. Litwinoff EMS, et al. 2017. Obes Res Clin Pract. 12:174. PubMed
  163. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  164. Maulhardt HA, et al. 2020. Invest New Drugs. 1618:38. PubMed
  165. Wang M, et al. 2021. iScience. 24(7):102766. PubMed
  166. Guey B, et al. 2014. Proc Natl Acad Sci U S A. 111:17254. PubMed
  167. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  168. Pattabiraman G, et al. 2021. Am J Physiol Renal Physiol. . PubMed
  169. Chen Y, et al. 2022. Stem Cells Int. 2022:1309684. PubMed
  170. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  171. Peltzer N, et al. 2018. Nature. 557:112. PubMed
  172. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  173. O'Boyle C, et al. 2020. Int J Stroke. 0.746527778. PubMed
  174. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  175. Tian F, et al. 2016. Nat Commun. 7:13283. PubMed
  176. Sen D, et al. 2016. PLoS One. 11:e0165064. PubMed
  177. Rossi G, et al. 2022. Sci Rep. 12:13380. PubMed
  178. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  179. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  180. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  181. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  182. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  183. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
RRID
AB_493714 (BioLegend Cat. No. 103127)
AB_493715 (BioLegend Cat. No. 103128)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV™ 395 anti-mouse CD45 30-F11 FC
Go To Top Version: 4    Revision Date: 04.20.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account